• BigBearPharma announces that Letermovir (LETEDX) has been approved in Laos

  September 20, 2024 - Vientiane, Laos - BigBearPharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapi···【Read More】

  Update: 26 May,2026Source: Haiou HealthViews: 656

• FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) Treatment for Chronic Hepatitis Delta Virus (HDV)

  FOSTER CITY, Calif.--(BUSINESS WIRE) May 22, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (···【Read More】

  Update: 25 May,2026Source: Haiou HealthViews: 248

• FDA Approves Inqovi for Acute Myeloid Leukemia

  FRIDAY, May 22, 2026 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of a···【Read More】

  Update: 25 May,2026Source: Haiou HealthViews: 254

• BigBear Pharma Announces Approval of Pralsetinib (PRASEDX) in Laos

  Vientiane, Laos, August 12, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer tre···【Read More】

  Update: 22 May,2026Source: Haiou HealthViews: 243

• Double "Zero" Breakthrough! Anti-cancer Drug from BigBear Pharma Laos Achieves First Export to ASEAN

  September 24, 2024 - Vientiane, Laos - Recently, BigBear Pharma Laos announced that it has received official permission from the Lao Ministry of Healt···【Read More】

  Update: 22 May,2026Source: Haiou HealthViews: 312

• Lusutrombopag manufactured by BigBear Pharmaceuticals approved in Laos

  Vientiane, Laos – October 08, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovativ···【Read More】

  Update: 21 May,2026Source: Haiou HealthViews: 277

• FDA Approves Ocrevus (ocrelizumab) for Pediatric Patients 10 Years of Age and Older with Relapsing-Remitting Multiple Sclerosis

  Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) intrave···【Read More】

  Update: 21 May,2026Source: Haiou HealthViews: 212

• BigBear Pharmaceuticals of Laos Successfully Obtains GMP Certification for Its Traditional Medicine Processing Plant

  Laos, October 7, 2023 – BigBear Pharmaceuticals of Laos is pleased to announce that its Traditional Chinese Medicine processing facility has successfu···【Read More】

  Update: 20 May,2026Source: Haiou HealthViews: 392

• FDA Approves Baxfendy (baxdrostat) as the First Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension

  May 18, 2026 – Baxfendy (baxdrostat) from AstraZeneca has received FDA approval as the world's first aldosterone synthase inhibitor (ASI) for use ···【Read More】

  Update: 20 May,2026Source: Haiou HealthViews: 259

• BigBear Pharma Announces Approval of Encorafenib (BRATODX) in Laos

  Vientiane, Laos – October 12, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovativ···【Read More】

  Update: 19 May,2026Source: Haiou HealthViews: 235

• EU Recommends Expanding New Indications for Nivolumab (Opdivo)

  Recently, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending chan···【Read More】

  Update: 19 May,2026Source: Haiou HealthViews: 241

• BigBear Pharma: Rooted in Laos, Aspiring for Global Reach as a Guardian of Public Health

  In Vientiane, the capital city of Laos, a modern pharmaceutical manufacturing base is emerging steadily. As a representative of officially licensed ch···【Read More】

  Update: 18 May,2026Source: Haiou HealthViews: 290

• FDA Approves Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi) as the First Interchangeable Biosimilars to Simponi and Simponi Aria

  May 15, 2026 — The FDA has approved Immgolis (golimumab-sldi) as an interchangeable biosimilar to Simponi (golimumab), and Immgolis Intri (golimumab-s···【Read More】

  Update: 18 May,2026Source: Haiou HealthViews: 203

• BigBear Pharma: Binimetinib (MEKTODX) Receives Approval from the Lao Ministry of Health

  Vientiane, Laos—October 12, 2024—BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treat···【Read More】

  Update: 14 May,2026Source: Haiou HealthViews: 213

• BigBear Pharma: A Beacon of Health Along the Mekong River, Setting a New Benchmark for Laos’ Pharmaceutical Industry

  In Vientiane, the capital of Laos nourished by the Mekong River, a modern pharmaceutical manufacturing base brims with vigorous vitality. As one of La···【Read More】

  Update: 13 May,2026Source: Haiou HealthViews: 291